title: No predictive value of serum interleukin-6 and transforming growth factor-beta1 in identifying patients with a first restenosis, recurrent restenosis or a history of restenosis.
abstract: BACKGROUND
  The efficacy of percutaneous coronary intervention (PCI) is limited by the need for repeat revascularization resulting from restenosis. The restenosis rate after treatment for in-stent restenosis (recurrent restenosis) is high (> 30%). Numerous studies have suggested the predictive value of interleukin 6 (IL-6) and transforming growth factor beta1 (TGF-beta1).
  
  
  METHODS
  We sought to determine whether serum levels of IL-6 and TGF-beta1 could help identify individuals with recurrent restenosis. Thirty seven patients with a history of stent implantation were enrolled and divided into three groups: (1) patients with a current, first restenosis (n = 9); (2) patients with current restenosis and at least one prior restenosis (recurrent restenosis) (n = 11), and (3) patients with a history of restenosis, but without current restenosis (n = 17).
  
  
  RESULTS
  The baseline profile was similar in all three groups. The median (25th-75th percentile) concentrations of IL-6 were: group 1 - 2.8 (1.4-5.5); group 2 - 2.6 (0.6-8.6); group 3 - 2.4 (0.9-4.7) p = 0.69 and TGF-beta1: group 1 - 3.6 (0.2-14.4); group 2 - 4.2 (1.8-57.6); group 3 - 6.6 (2.8-30.0) p = 0.57. Moreover we found no correlation, either between diameter stenosis and IL-6 (R = 0.10; p = 0.38) or TGF-beta1 (R = 0.10; p = 0.57). Both IL-6 (AUC 0.59 p = 0.4 and AUC 0.51 p = 0.9) and TGF-beta1 (AUC 0.64 p = 0.2 and AUC 0.50 p = 0.9) failed to provide significant results in receiver-operating characteristic analysis.
  
  
  CONCLUSIONS
  We report that there is no association between the severity of diameter stenosis (restenosis) and IL-6 or TGF-beta1 concentrations. Our findings might suggest that levels of IL-6 and TGF-beta1 have no predictive value for identifying patients with recurrent restenosis.
authors.affiliation: 3rd Department of Cardiology, Silesian Center for Heart Disease, Silesian Medical University, Zabrze, Poland. bartekh@mp.pl
authors.forename: Bartosz
authors.initials: B
authors.lastname: Hudzik
authors.forename: Janusz
authors.initials: J
authors.lastname: Szkodzinski
authors.forename: Wojciech
authors.initials: W
authors.lastname: Romanowski
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Wilczek
authors.forename: Rafal
authors.initials: R
authors.lastname: Wojnar
authors.forename: Andrzej
authors.initials: A
authors.lastname: Lekston
authors.forename: Lech
authors.initials: L
authors.lastname: Polonski
authors.forename: Barbara
authors.initials: B
authors.lastname: Zubelewicz-Szkodzinska
mesh_terms: D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000097:blood* / Q000175:diagnosis* / Q000000981:diagnostic imaging; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012008:Recurrence; D053773:Transforming Growth Factor beta1 / Q000097:blood*
chemical_list: C508600:IL6 protein, human; D015850:Interleukin-6; C508960:TGFB1 protein, human; D053773:Transforming Growth Factor beta1